Mapping prion pathology in mice using quantitative imaging: an MRI study
E. Demetriou, M. Tachrount, M. Ellis, J. Linehan, S. Brandner, J. Collinge, S. H. Mead, K. Shmueli, M. Farrow, X. Golay
Abstract
Human prion diseases are fatal neurodegenerative disorders which cause cognitive impairment and neurological deficits. Additional measures of tissue status are necessary for improving the sensitivity and specificity of clinical diagnosis as in many cases clinical forms of prion disease are commonly mistaken for other forms of dementia. To that effect, we developed a set of quantitative magnetic resonance-based tools, including magnetic resonance spectroscopy (MRS), magnetization transfer ratio (MTR) and quantitative T1 and T2 imaging to study the course of the disease in an animal model of prion disease. Using in vivo MTR, significant changes were detected in the cortex and thalamus of late-stage prion -infected mice as compared to littermates. In addition, we found a significant increase of MTR in thalamus and cortex of 80 dpi healthy mice when compared with 160 dpi healthy mice suggestive of changes occurring during the development of the brain. Using quantitative T2 mapping, significantly higher values were measured in thalamus of prion mice at all stages of the disease (T2=40ms) while T1 was found to be significantly higher in cortex (T1=1.89s) and hippocampus, albeit only in late-stage prion mice as compared to aged-matched controls (T1=1.67s). Using quantitative MRS significant changes were detected in glutamate (Glu) and myo-inositol (Ins) at all stages of prion disease when compared with the control group. NAA, Cr, Lactate and Lipids were only found to be significantly different at early and late stages of the disease while Taurine (Tau) was only significantly increased in the asymptomatic stage without any significant change at early and late stages of the disease. These changes in MRI and MRS signals, which precede clinical signs of disease, could provide insights into the pathogenesis of this disease and may enable early detection of pathology.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Can Chemical Exchange Saturation Transfer (CEST MRI) be used as biomarker of disease progression in Prion Disease?
E. Demetriou, M. Tachrount, … X. Golay·bioRxiv·Dec 16, 2021
- Genome-wide transcriptomics identifies an early preclinical signature of prion infection
Silvia Sorce, Mario Nuvolone, … Adriano Aguzzi·PLoS PathogensPeer-reviewed·Jun 29, 2020
- Loss of region-specific glial homeostatic signature in prion diseases
Natallia Makarava, Jennifer C. Chang, … Ilia V. Baskakov·bioRxiv·Oct 30, 2019
- Longitudinal magnetic resonance imaging and spectroscopy in a mouse model of cuprizone-induced demyelination
Esther H. Walters, Davide Di Censo, … Diana Cash·Experimental NeurologyPeer-reviewed·Aug 11, 2026
- Distinguishing microgliosis and tau deposition in the mouse brain using paramagnetic and diamagnetic susceptibility source separation
Jayvik Joshi, Minmin Yao, … Manisha Aggarwal·Imaging NeurosciencePeer-reviewed·Jan 1, 2025
- Domain-specific quantification of prion protein in cerebrospinal fluid by targeted mass spectrometry
Eric Vallabh Minikel, Eric W. Kuhn, … Steven A. Carr·Molecular & Cellular ProteomicsPeer-reviewed·Sep 26, 2019